These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Volume-based parameters on FDG PET may predict the proliferative potential of soft-tissue sarcomas. Kitao T; Shiga T; Hirata K; Sekizawa M; Takei T; Yamashiro K; Tamaki N Ann Nucl Med; 2019 Jan; 33(1):22-31. PubMed ID: 30196378 [TBL] [Abstract][Full Text] [Related]
3. Predictive and prognostic potential of volume-based metabolic variables obtained by a baseline Garcia-Vicente AM; Pérez-Beteta J; Amo-Salas M; Molina D; Jimenez-Londoño GA; Soriano-Castrejón AM; Pena Pardo FJ; Martínez-González A Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):73-79. PubMed ID: 29102649 [TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma. Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088 [TBL] [Abstract][Full Text] [Related]
5. Metabolic Tumor Burden Assessed by Dual Time Point [ Garcia-Vicente AM; Pérez-Beteta J; Pérez-García VM; Molina D; Jiménez-Londoño GA; Soriano-Castrejón A; Martínez-González A Mol Imaging Biol; 2017 Aug; 19(4):636-644. PubMed ID: 27981471 [TBL] [Abstract][Full Text] [Related]
6. Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times. Liu H; Chen P; Wroblewski K; Hou P; Zhang CP; Jiang Y; Pu Y Nucl Med Commun; 2016 Jan; 37(1):50-6. PubMed ID: 26426969 [TBL] [Abstract][Full Text] [Related]
7. The prognostic value of Grut H; Dueland S; Line PD; Revheim ME Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):218-225. PubMed ID: 29026950 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369 [TBL] [Abstract][Full Text] [Related]
9. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma]. Wu LL; Liang JH; Wang L; Xu W; Ding CY Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850 [No Abstract] [Full Text] [Related]
10. The value on SUV-derived parameters assessed on Liao X; Liu M; Li S; Huang W; Guo C; Liu J; Xiong Y; Zhang J; Fan Y; Wang R BMC Med Imaging; 2023 Apr; 23(1):49. PubMed ID: 37020286 [TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents. Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043 [TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of Volumetric Parameters Measured by Pretreatment 18F FDG PET/CT in Patients With Cutaneous Malignant Melanoma. Son SH; Kang SM; Jeong SY; Lee SW; Lee SJ; Lee J; Ahn BC Clin Nucl Med; 2016 Jun; 41(6):e266-73. PubMed ID: 27055144 [TBL] [Abstract][Full Text] [Related]
13. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy. Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011 [TBL] [Abstract][Full Text] [Related]
14. Lymph node standardized uptake values at pre-treatment Jeong Y; Baek S; Park JW; Joo JH; Kim JS; Lee SW Br J Radiol; 2017 Mar; 90(1071):20160239. PubMed ID: 28008776 [TBL] [Abstract][Full Text] [Related]
15. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial. Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281 [TBL] [Abstract][Full Text] [Related]
16. Pre-treatment metabolic tumor volume predicts tumor metastasis and progression in high-grade salivary gland carcinoma. Almuhaimid TM; Lim WS; Roh JL; Oh JS; Kim JS; Kim SJ; Choi SH; Nam SY; Kim SY J Cancer Res Clin Oncol; 2018 Dec; 144(12):2485-2493. PubMed ID: 30293119 [TBL] [Abstract][Full Text] [Related]
17. Boktor RR; Berlangieri SU; Lau E; Lim A; Gong SJ; Li X; Scott AM Ann Nucl Med; 2024 Sep; ():. PubMed ID: 39341996 [TBL] [Abstract][Full Text] [Related]
18. The Role of the Metabolic Parameters of Wang D; Liu X; Wang W; Huo L; Pan Q; Ren X; Zhang F; Hu K Front Oncol; 2021; 11():698744. PubMed ID: 34490094 [TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of metabolic tumor volume and total lesion glycolysis in patients with advanced cervical carcinoma. Calles-Sastre L; Mucientes-Rasilla J; San-Frutos Llorente LM; Royuela A; Garcia-Espantaleón Navas M; Herrero Gámiz S; Pérez-Medina T Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):17-21. PubMed ID: 30366731 [TBL] [Abstract][Full Text] [Related]
20. The correlation of Qu YH; Long N; Ran C; Sun J Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]